Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such
as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of …

Background Gefitinib and erlotinib are superior to chemotherapy in terms of progression-free-
survival (PFS), objective response rate (ORR) and disease control rate (DCR) in patients …

Background: We performed an individual patient data meta-analysis to examine the impact
of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) …

7597 Background: Compared to chemotherapy, 1st line treatment with EGFR-TK inhibitors
results in superior progression-free survival (PFS) in Asian patients with advanced NSCLC …

8005 Background: Despite the development of EGFR tyrosine kinase inhibitors, median
progression-free survival (PFS) is only about 13 months in patients with EGFR mutation …

e20718 Background: Inhibition of epidermal growth factor receptors (EGFR) bearing somatic
mutations in the tyrosine kinase domain is an important molecular target in the treatment of …

LBA7501 Background: While the benefit of EGFR tyrosine kinase inhibitors in the treatment
of patients with NSCLC harboring EGFR mutations has been widely established, their value …

Purpose: Most lung cancers with activating epidermal growth factor receptor (EGFR)
mutations respond to gefitinib; however, resistance to this tyrosine kinase inhibitor (TKI) …

Somatic mutations in the epidermal growth factor receptor (EGFR) have emerged as
important biomarkers in predicting the likelihood of tumor response to the EGFR tyrosine …

© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2012; 1
(3): 219-223 www. tlcr. org reported for gefitinib (15, 16). Thus, phase II studies laid a solid …